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Background: Improvement of current GVHD prophylactic therapies remains an important goal in the allo-HSCT. We
have described a novel prophylaxis regimen in a single institution trial. The Chinese Bone Marrow Transplant Cooperative
Group (CBMTCG) initiated a phase II multicenter study.
Methods: The study was designed as a prospective, single arm phase II open-label, multicenter clinical trial. The
primary endpoint was improvement of aGVHD by 25% over historical control (40%) in Chinese patients. 508 patients
were enrolled. All of the patients received cyclosporine A (CsA), methotrexate (MTX) and mycophenolate mofetil (MMF)
(0.5-1.0 g daily for 30 days) as GVHD prophylaxis regimen.
Results: The primary endpoint was met with cumulative incidences of grades 2 to 4 and grades 3 to 4 aGVHD of
23.2% and 10.3%, respectively. Incidence for cGVHD was 67.4%. The non-relapse mortality (NRM) rate was 18.4% at
2 years. The probabilities of leukemia free survival (LFS) for non-advanced stage and advanced stage patients at 2 years
were 69.7% and 44.8% respectively (p = 0.000). Recipient age≥ 40 years, advanced stage and Busulfan-Fludarabine
(BuFlu) conditioning regimen were identified as major risk factors for aGVHD. Recipient age≥ 40 years, BuFlu conditioning
regimens, female donor/male recipient and prior aGVHD were associated with cGVHD. Despite lower RM (relapse mortality),
patients with grade 2–4 aGVHD had higher NRM and worse OS and LFS compared to patients with grade 0–1 aGVHD. In
contrast, patients with cGVHD had better OS and LFS and lower RM compared to patients without cGVHD.
Conclusion: The novel GVHD regimen decreased the risk for aGVHD by 42% without improving the risk for cGVHD
compared to historical controls. Development of aGVHD was associated with worse OS and LFS as well as higher NRM. In
contrast, cGVHD was associated with improved OS and LFS likely attributed to a GVL effect.
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Despite the use of prophylaxis regimens, Graft-versus-host
disease (GVHD) remains a major cause for mortality
and morbidity with allogeneic hematopoietic stem cell
\transplantations (allo-HSCT). It is also the primary cause
of death in 16% and 18% of deaths after HLA-match sib-
ling and unrelated donor allo-HSCT respectively [1]. A
combination consisting of a calcineurin inhibitor (CNI),
cyclosporine or tacrolimus, and either methotrexate,
mycophenolate mofetil (MMF), or sirolimus are consid-
ered to be the standard prophylaxis regimens. However,
review of US and European literature indicates that acute
GVHD (aGVHD) still occurs in 35% to 65% of BMT pa-
tients receiving human leukocyte antigen (HLA)–matched
sibling transplants, and even more frequently in unrelated
donor transplant recipients [2-6]. Analysis of Chinese
transplant registries as well as relevant Chinese publica-
tions calculate the overall incidence for grade 2–4 aGVHD
at approximately 40% [7-9]. Thus, improved prophylactic
approaches are needed. Most strategies employed to
reducing both aGVHD and chronic GVHD (cGVHD)
(e.g. T-cell depletion) have significant drawbacks as
they are offset by high rates of graft failure, malignancy
relapse, infections, and Epstein-Barr virus-associated
lymphoproliferative disorders [10-12]. For patients with
hematologic malignancies, “standard of care GVHD
prophylaxis” seems to have struck a reasonable bal-
ance between preventing undesirable graft-versus-host
reactions and retaining desirable graft-versus-tumor
effects [13]. The risk for developing GVHD depends
on various factors which are determined by the pa-
tient, disease characteristics as well as by the graft, its
processing, and the transplant procedure/conditioning
regimen employed. Thus far, no trials have been con-
ducted where GVHD prophylaxis has been individually
stratified to the probability of GVHD occurrence or
disease relapse.
We have previously described a combination prophylaxis
regimen consisting of cyclosporine A (CsA), methotrexate
(MTX) and a low-dose, short-course mycophenolate
mofetil (MMF) (0.5 daily for 30 days) in a single institu-
tion trial for a cohort of 100 patients with hematologic
malignancies who underwent HLA-matched sibling allo-
HSCT. The rationale behind a regimen designed with a
short course of MMF was to primarily improve aGVHD
without substantially impacting the incidence of cGVHD
because of the associated beneficial GVL effect. Although
cGVHD is an undesired complication of BMT, we hypoth-
esized that this strategy would lead to reduced leukemia
relapse to an extent which would result in an overall sur-
vival net benefit across all patients. We did indeed report
a substantial decrease in the risk for aGVHD in our initial
study [14]. In order to confirm the effectiveness of this
new GVHD prophylaxis regimen, the Chinese BoneMarrow Transplant Cooperative Group (CBMTCG) initi-
ated a prospective, open-label, multicenter clinical trial
using this prophylaxis regimen in 508 patients. Further-
more, we analyzed additional risk factors for GVHD in
this population consisting entirely of Chinese patients.
Patients and methods
Patient eligibility
The trial was designed as a prospective, open-label,
multicenter clinical protocol and was conducted by the
Chinese Bone Marrow Transplant Cooperative Group
(CBMTCG), a cooperative transplant group consisting
of seven Chinese transplant centers: the Peking University
Institute of Hematology, n = 264; the First Affiliated
Hospital of Guangxi Medical University, n = 81; the
First Affiliated Hospital of Xinjiang Medical University,
n = 50; Changzheng Hospital, the Second Military Medical
University, n = 10; Kunming General Hospital of Chengdu
Command, n = 55; Nanfang Hospital Southern Medical
University, n = 28; First Affiliated Hospital Chongqing
Medical University, n = 20. Patients with hematologic ma-
lignancies in need of an allo-HSCT who had an HLA-
identical sibling donor were eligible. Additional eligibility
criteria included: 1) Age: 15 to 65 years old; 2) Medically
suitable to tolerate a myeloablative (MA) conditioning
regimen; 3) Eastern Cooperative Oncology Group (ECOG)
performance status ≤ 2; 4) Bilirubin ≤ 2 mg/dL, 5) creatin-
ine < 1.5 times the upper limit of normal, 6) preserved
heart and lung function; 7) Negative infectious evaluation
(viral, bacterial and fungal). Between August 2007 and
October 2010, 508 patients were enrolled and com-
pleted treatment. The protocol was approved by the In-
stitutional Review Board of each center, and prior
treatment written informed consent was obtained from
both patients and donors. All participating institutions
and investigators had subscribed to the principles and
conduct of the WMA Declaration of Helsinki - Ethical
Principles for Medical Research Involving Human Subjects.
Patient characteristics are summarized in Table 1.
Conditioning regimen
The protocol permitted use of three myeloablative condi-
tioning regimens at investigators discretion: 1) BuCy:
Busulfan (12–16 mg/kg) and cyclophosphamide (120 mg/kg)
was given to 347 patients. 2) BuFlu: Busulfan (12–16 mg/kg)
combined with Fludarabine (250 mg or 150 mg/m2) was
given to 134 patients and Fludarabine (250 mg) combined
with Melphalan (140 mg/m2) was given to one patient. 3)
TBICy: TBI (7.7-10.0 Gy) and cyclophosphamide
(120 mg/kg) was given to 26 patients.
Procurement of hematopoietic stem cells
The protocol permitted use of two sources of hematopoietic
stem cells at investigators discretion: 1) Peripheral Blood
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AML, acute myeloid leukemia; CR, complete remission; PR, partial remission; NR,
nonremission; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia;
CP, chronic phase; AP, accelerated phase; BC, blast crisis; MDS, myelodysplastic
syndrome; RAEB, refractory anemia with excess blasts; Non-advanced stage, including
acute leukemia (AL) in CR, CML in CP and AP, MDS-RAEB, Advanced stage, including
AL in NR and CML in BC, PB, peripheral blood; BM, bone marrow; TBI, total
body irradiation; Cy, cyclophosphamide; Bu, busulfan; MMF, mycophenolate
mofetil, Flu, fludarabin.
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http://www.jhoonline.org/content/7/1/59(PB): 258 patients were grafted with human granulocyte
colony-stimulating factor (rHuG-CSF)–mobilized peripheral
blood stem cells (PBSC).Donors were treated with G-CSF
at a dose of 5–10 ug/kg/d subcutaneously for 4 consecutive
days starting 5 days before leukapheresis with a target
CD34 cell number of at least 4 × 106 CD34cells per
kilogram of recipient weight. The median numbers of
mononuclear cells (MNC) and CD34 cells infused
were 9.11 (2.93-17.6) × 108/kg and 4.25 (1.15-16.6) ×
106/kg, respectively. 2) PB + BM: 250 patients were
grafted with a combination PBSC and bone marrow
stem cells (BMSC). PBSC were harvested after donors
were treated with G-CSF at a dose of 5–10 ug/kg/d
subcutaneously for 4 consecutive days and bone marrow
was harvested on the following day by standard technique
using general anesthesia. The ratio of CD34 cells numbers
of PB to BM was 2–4:1. The median numbers of MNCs
and CD34 cells infused were 7.48(3.14-12.53) × 108/kg
and 2.34 (0.40-7.45) × 106/kg, respectively. This com-
bination grafting procedure is commonly used in China
and based on publications previously describing im-
proved outcomes [15].
GVHD prophylaxis
All of the transplant recipients received CsA, MTX, and
a low-dose, short-course MMF. The dosage of CsA was
2.5-3 mg/kg/d, i.v., and CsA was administered from day
1 before transplantation until recovery of bowel func-
tion. At that point, the patient was switched to oral CsA.
Serum CsA concentration was monitored, and the dos-
age was adjusted to achieve serum concentrations ran-
ging between 150–300 ng/ml. MMF was administered
orally as doses of 0.5-1.0 g/d from day 1 before trans-
plantation to day 30 after transplantation. The dose was
assigned by weight, with patients up to and below 60 kg
receiving 0.5 mg and patients above 60 kg receiving
1.0 mg. MTX was administered i.v. at doses of 15 mg/m2
on day 1 and 10 mg/m2 on days 3, 6 and 11. Fifty-nine
patients omitted the 4th dose of MTX. First-line ther-
apy of clinically significant aGVHD consisted of meth-
ylprednisolone (MP) 1 to 2 mg/kg/d. Patients whose
GVHD was refractory to steroid therapy could receive sec-
ondary therapy such as tacrolimus, CD25 antibody or
other therapies at investigator discretion.
Definitions and assessments
Disease status at transplant was classified as “non-advanced
stage” or “advanced stage.” The patients were categorized
as “ non-advanced stage” if they were in complete remission
(CR) from acute leukemia (AL) regardless of cytogenetics,
chronic myelogenous leukemia (CML) in chronic phase (CP)
or accelerated phase (AP), and myelodysplastic syndrome
(MDS) with a blast count <20%. “Advanced stage” was de-
fined as AL not in remission (NR) or CML in blast crisis
Figure 1 Cumulative incidences of aGVHD (Figure 1-A) and cGVHD (Figure 1-B) in 508 patients who underwent sibling identical
allo-HSCT and CSA/MTX/MMF GVHD prophylaxis.
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Table 2 Risk factors for acute graft-versus-host disease determined by univariate analysis
Variable N Grade 2–4 aGVHD Grade 3–4 aGVHD
HR 95% CI P HR 95% CI P
Age for recipients,years
<40 305 1.00 1.00
≥40 189 1.62 1.11-2.36 0.013 1.14 0.64-2.06 0.656
Age for donor, years
<40 306 1.00 1.00
≥40 188 1.50 1.01-2.24 0.046 0.90 0.48-1.68 0.732
Age for donor and recipients, years
Recipients < 40 and donor < 40 260 1.00 1.00
Recipients < 40 and donor≥ 40 56 1.08 0.54-2.16 0.821 0.58 0.17-1.92 0.370
Recipients≥ 40 and donor < 40 46 1.23 0.60-2.52 0.578 0.97 0.34-2.80 0.953
Recipients≥ 40 and donor ≥ 40 132 1.77 1.13-2.77 0.013 1.03 0.51-2.08 0.929
Donor-recipient gender
Other 354 1.00 1.00
Female→Male 140 1.13 0.74-1.71 0.574 1.19 0.64-2.21 0.575
Stem cell source
BM + PB 240 1.00 1.00
PB 254 1.17 0.80-1.70 0.430 1.54 0.85-2.78 0.155
Leukemia type
AL 305 1.00 1.00
CML 155 0.71 0.46-1.12 0.142 0.76 0.39-1.47 0.411
Conditioning regimen
BuCy 341 1.00 1.00
TBICy 24 1.75 0.80-3.81 0.160 2.20 0.66-7.36 0.199
BuFlu 128 1.63 1.08-2.46 0.020 2.86 1.57-5.20 0.001
Donor-recipient blood type
Match 306 1.00 1.00
Mis-match 188 0.93 0.62-1.40 0.730 0.85 0.47-1.58 0.611
Disease stage
Non-advanced 429 1.00 1.00
Advanced 65 1.67 1.01-2.77 0.047 3.17 1.67-6.03 0.000
MMF dose
0.5 g/d 128 1.00 1.00
1.0 g/d 366 1.39 0.87-2.22 0.168 1.01 0.52-1.94 0.983
aGVHD, acute graft-versus-host disease; AL, acute leukemia; CML, chronic myelogenous leukemia; BM, bone marrow; BP, peripheral blood; TBI, total body irradiation; Cy,
cyclophosphamide; Bu, busulfan; MMF, mycophenolate mofetil; Flu, fludarabin; Non-advanced stage, including acute leukemia (AL) in CR, CML in CP and AP, MDS-RAEB;
Advanced stage, including AL in NR and CML in BC.
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an absolute neutrophil count (ANC) of 0.5 × 109/L or more
for 3 consecutive days, and platelet engraftment was defined
as the first day of platelets ≥ 20 × 109/L for 7 consecutive days
without transfusion. Primary engraftment failure was defined
as the absence of donor-derived myeloid cells at day 60 in pa-
tients surviving beyond day 28 after transplantation. Chronic
GVHD was evaluated in patients who survived for greater
than 100 days and had a sustained engraftment. Acute andchronic GVHD were defined according to published standard
criteria [16,17]. Relapse was defined as evidence for the pres-
ence of morphological disease in peripheral blood, marrow,
or extramedullary sites. Leukemia-free survival (LFS) was de-
fined as continuous CR at the last follow-up.
Statistical methods
For our Chinese population treated in China, historically
grade 2–4 aGVHD is reported to be around 40% [7-9].
Table 3 Multi-factor analysis of risk factors for acute graft-versus-host disease determined
Variable N Grade 2–4 aGVHD Grade 3–4 aGVHD
HR 95% CI P HR 95% CI P
Age for recipients,years
<40 305 1.00 1.00
≥40 189 1.65 1.13-2.41 0.010 1.19 0.66-2.14 0.565
Conditioning regimen
BuCy 341 1.00 1.00
TBICy 24 1.67 0.76-3.71 0.205 1.71 0.50-4.61 0.395
BuFlu 128 1.58 1.04-2.39 0.033 2.49 1.35-4.61 0.004
Disease stage
Non-advanced 429 1.00 1.00
Advanced 65 1.44 0.85-2.43 0.172 2.45 1.26-4.78 0.009
aGVHD, acute graft-versus-host disease; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Flu, fludarabin; Non-advanced stage, including acute
leukemia (AL) in CR, CML in CP and AP, MDS-RAEB; Advanced stage, including AL in NR and CML in BC.
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http://www.jhoonline.org/content/7/1/59Our primary endpoint was to improve the grade 2–4
aGVHD incidence by 25% over historical control (reduce
to 30%). Under the assumptions of 90% power and a two
sided error rate of 0.05 we calculated the trial a size of 477
patients. By estimating a 5% dropout rate, we planned our
sample size at 500 patients. Achieving the primary end-
point was calculated to be associated with a HR of 0.75.
Cumulative incidences were estimated for engraftment,
aGVHD, cGVHD, non-relapse mortality (NRM), relapse
mortality (RM) and relapse in order to evaluate competing
risks. The competing risk for engraftment was death with-
out engraftment; the competing risk for GVHD was death
without GVHD and graft rejection; relapse was a compet-
ing risk for NRM; and NRM was a competing risk for
relapse. The time of GVHD occurrence was defined
from day 1 after graft infusion to the onset of any grade
of GVHD; aGVHD was censored at day 100 after HSCT
and cGVHD was censored at the last follow-up visit.
The worst stage of the GVHD was assessed as the de-
gree of the GVHD reported. The probabilities of overall
survival (OS) and LFS were estimated by the Kaplan-
Meier method [18]. Potential prognostic factors were
evaluated in univariate analyses by the log-rank test,
with a P-value of less than 0.05 being considered statis-
tically significant. The demographics of patients and do-
nors, the underlying disease, disease status, conditioning
regimens, the source of the graft, MMF doses and other
pre-transplant parameters were included in the univariate
analyses. In the multivariate analysis, all of the factors
found to influence the outcomes in the univariate analysis
with a P < 0.1 were included into a Cox proportional
hazard model using a forward: conditional method
(SAS version 8.2, SAS Institute, Cary, NC, and S Plus
2000, Mathsoft, Seattle, WA). Data cut off for survival
follow-up was October 31, 2011. The median follow-up
time was 22.8 months.Results
Engraftment
503 (99.0%) patients achieved sustained myeloid en-
graftment. The median time to reaching an ANC above
0.5 × 109 cells/L was 14 (7–24) days. During the follow-up
period, 496 patients (97.6%) exhibited platelet engraft-
ment, and the median time to reach a platelet count above
20 × 109 cells/ L was 13 (6–124) days.
Graft-versus-host disease
At 100 days after transplantation, the cumulative inci-
dence was 23.2% (95% CI, 21.2%-25.2%) for grade 2 to 4
aGVHD, and 10.3% (95% CI, 9.8%-11.8%) for grade 3 to
4 aGVHD (Figure 1-A). The cumulative incidence was
67.4% (95% CI, 64.9%-69.9%) for total cGVHD and
45.1% (95% CI, 42.0%-48.2%) for extensive cGVHD at
2 years after transplantation (Figure 1-B).
Analysis of risk factors for aGVHD
The risk factors for aGVHD determined by univariate
analysis are listed in Table 2. By univariate analysis, pa-
tient and donor age ≥ 40 years old, advanced stage as
well as BuFlu conditioning regimen were associated with
grade 2 to 4 aGVHD incidence. Advanced stage, BuFlu
conditioning regimen were associated with the risk of
grade 3 to 4 aGVHD. Donor-recipient sex match, donor-
recipient blood type match, MMF dose and CML were
not associated with grade 2 to 4 or grade 3 to 4 aGVHD
incidences. Because in our study all donors were siblings,
the age range for patients and donors remained relatively
narrow (r = 0.797, p = 0.000). For recipients younger than
40 years of age, no impact of donor age on the incidence
or severity of aGVHD was observed. Older patients
(≥40 years) had higher odds to experience grade 2–4
aGVHD than the younger patients (<40 years) (30.0%
vs 18.5%, p = 0.01).Patients transplanted at advanced stage
Table 4 Univariate analysis of risk factors for chronic graft-versus-host disease
Variable N cGVHD Extensive cGVHD
HR 95% CI P HR 95% CI P
Age for recipients, years
<40 286 1.00 1.00
≥40 180 1.34 1.06-1.70 0.016 1.54 1.12-2.11 0.007
Age for donor, years
<40 288 1.00 1.00
≥40 178 1.10 0.848-1.43 0.473 1.362 0.971-1.912 0.074
Age for donor and recipients, years
recipients < 40 and donor < 40 243 1.00 1.00
recipients < 40 and donor ≥ 40 52 0.72 0.46-1.15 0.174 0.90 0.49-1.64 0.729
recipients≥ 40 and donor < 40 47 1.24 0.82-1.88 0.314 1.46 0.84-2.53 0.179
recipients≥ 40 and donor≥ 40 124 1.38 1.03-1.85 0.034 1.76 1.20-2.59 0.004
Donor-recipient gender
Other 336 1.00 1.00
Female→Male 130 1.48 1.15-1.90 0.002 1.92 1.39-2.65 0.000
Stem cell source
BM + PB 241 1.00 1.00
PB 225 0.51 0.40-0.65 0.000 0.30 0.21-0.43 0.000
Leukemia type
AL 287 1.00 1.00
CML 145 1.04 0.80-1.34 0.778 0.94 0.66-1.35 0.747
Conditioning regimen
BuCy 326 1.00 1.00
TBICy 23 0.66 0.34-1.29 0.226 0.56 0.21-1.54 0.264
BuFlu 116 1.49 1.15-1.94 0.003 1.96 1.41-2.73 0.000
Donor-recipient blood type
Match 273 1.00 1.00
Mis-match 193 1.14 0.89-1.45 0.301 1.18 0.85-1.60 0.317
Disease Stage
Non-advanced 415 1.00 1.00
Advanced 51 1.19 0.80-1.78 0.389 0.96 0.54-1.70 0.890
aGVHD
No 332 1.00 1.00
Yes 134 1.82 1.42-2.34 0.000 2.14 1.55-2.96 0.000
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; BM, bone marrow; BP, peripheral blood; AL, acute leukemia; CML, chronic myelogenous
leukemia; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MMF, mycophenolate mofetil; Flu, fludarabin; Non-advanced stage, including acute leukemia (AL)
in CR, CML in CP and AP, MDS-RAEB; Advanced stage, including AL in NR and CML in BC.
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aGVHD (30.8% vs 21.7%, p = 0.045) and grade 3–4
aGVHD (21.8% vs 8.5%, p = 0.000) when compared to
patients who were transplanted at non-advanced stage.
By multivariate analysis, patient age ≥ 40 years and BuFlu
conditioning regimen were associated with grade 2 to 4
aGVHD incidence. Advanced stage and BuFlu condition-
ing regimen were associated with the risk of grade 3 to 4
aGVHD (Table 3).Analysis of risk factors for cGVHD
Risk factors for cGVHD determined by univariate ana-
lysis are listed in Table 4. By univariate analysis, patient
age ≥ 40 years old, female donor/male recipient, BuFlu
regimen for conditioning and prior aGVHD were the
risk factors for both cGVHD and extensive cGVHD.
Univariate analysis did not identify donor age, advanced
stage, donor-recipient blood type match or CML to be risk
factors for cGVHD and extensive cGVHD. Patients ≥
Table 5 Multi-factor analysis of risk factors for chronic graft-versus-host disease
Variable N cGVHD Extensive cGVHD
HR 95% CI P HR 95% CI P
Age for recipients, years
<40 286 1.00 1.00
≥40 180 1.24 0.96-1.59 0.093 1.35 0.97-1.87 0.072
Donor-recipient gender
Other 336 1.00 1.00
Female→Male 130 1.35 1.04-1.75 0.026 1.67 1.20-2.34 0.002
Conditioning regimen
BuCy 326 1.00 1.00
TBICy 23 0.62 0.30-1.24 0.175 0.91 0.20-1.50 0.244
BuFlu 116 1.38 1.05-1.81 0.020 1.69 1.20-2.39 0.003
aGVHD
No 332 1.00 1.00
Yes 134 1.73 1.34-2.23 0.000 1.94 1.39-2.69 0.000
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Flu, fludarabin.
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oping cGVHD and extensive cGVHD than younger
patients (<40 years) (75.9% vs 62.3%, p = 0.016) and
(55.9% vs 38.6%, p = 0.007).No significant differences
for cGVHD and extensive cGVHD were found for pa-
tients transplanted at non-advanced stage or advanced
stage (67.3% vs 62.5%, p = 0.374) and (45.6% vs 33.0%,
p = 0.888). Multivariate analysis confirmed female donor/
male recipient, BuFlu regimen for conditioning and
prior aGVHD as risk factor for cGVHD and extensive
cGVHD (Table 5).Survival, relapse and long-term follow-up
As of Apr 30, 2011, 377 patients were alive following
transplantation, with a median survival time of 22.8 m
(range: 6-52 m). Probabilities for OS and LFS in all pa-
tients at 2 years were 68.0% (95% CI =63.3%-75.8%) and
66.0% (95% CI =63.3%-75.8%) respectively. Probabilities
for OS in patients transplanted at non-advanced stage
and advanced stage at 2 years were 71.4% (95% CI =65.9%-
77.0%) and 41.8% (95% CI =20.9%-62.6%) (p = 0.000), re-
spectively. The probabilities of LFS in non-advanced
stage and advanced stage patients at 2 years were 69.7%Table 6 Comparison of outcomes in patients between with an
0-1 aGVHD% (95% CI) n = 386 2-4 aGVHD% (95% CI) n = 108 P
NRM 14.3% (CI = 10.7%-19.3%) 32.0% (CI = 23.4%-43.9%) 0.0
RM 20.6% (CI = 16.2%-26.3%) 8.6% (CI = 4.2%-17.8%) 0.0
OS 69.4% (CI = 63.2%-75.6%) 62.7% (CI = 52.6%-72.9%) 0.0
LFS 68.0% (CI = 62.5%-73.5%) 61.0% (CI = 50.8%-71.1%) 0.0
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; N
OS, overall survival.(95% CI =64.7%-74.8%) and 44.8% (95% CI =30.7%-58.9%)
(p = 0.000), respectively.
Sixty-nine patients relapsed after transplantation, reach-
ing a cumulative relapse of 17.7% (95% CI, 15.6%-19.8%) at
2 years. The NRM rate was 4.3% (95% CI = 3.4% - 5.2%)
and 18.4% (95% CI = 16.3%-20.5%) at 100 days and 2 years,
respectively. 53 out of 131 patients died of leukemia re-
lapse. Seventy-eight patients died from other causes than
relapse. The most frequent cause of death was infection,
specifically, pneumonia. Severe GVHD was determined as
cause of death in nineteen patients.Comparison of outcomes in patients between with and
without acute and/or chronic GVHD
In order to analyze the impact of GVHD on the overall
clinical outcomes of our patients, we compared outcomes
for patients with and without acute and/or chronic GVHD
(Table 6). Although the patients with grade 2–4 aGVHD
had lower RM, they had higher NRM and worse OS and
LFS when compared with the patients grade 0–1 aGVHD.
In contrast, patients with cGVHD had improved OS
and LFS and lower RM compared to patients without
cGVHD (Table 6).d without acute and/or chronic GVHD
Non- cGVHD% (95% CI) n = 189 cGVHD% (95% CI) n = 277 P
00 15.7% (CI = 10.6%-23.2%) 12.1% (CI = 8.3%-17.6%) 0.194
36 25.4% (CI = 19.0%-34.0%) 11.6% (CI = 7.6%-17.5%) 0.000
09 62.0% (CI = 53.0%-71.1%) 80.0% (CI = 73.5%-86.4%) 0.000
47 61.8% (CI = 53.9%-69.7%) 77.4% (CI = 71.5%-83.3%) 0.000
RM, non-relapse mortality; RM, relapse mortality; LFS, leukemia free survival;
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Although GVHD has been recognized more than fifty
years as a complication of allo-HSCT, current prophylactic
therapies remain insufficient and a high medical need to
improve outcomes remains [19-21]. Thus far, no signifi-
cant progress has been made in developing novel aGVHD
regimens and most approaches are not improved over his-
torical results. Although Devine et al. reported in their
study grade 2–4 aGVHD in only 22.4% and extensive
cGVHD of 6.8%, this was offset by only 58% 3 years DFS
in patients transplanted in AML-CR1. Likely, this was re-
lated to graft T cell depletion (TCD) which was part of the
GVHD prophylaxis in this study [22]. Compared to his-
toric transplant results derived from China, European
and US centers, this multicenter trial demonstrates a
substantial decrease of aGVHD in HLA-matched sibling
allo-HSCT without increasing disease relapse or adversely
impacting survival in standard risk patients, Our out-
comes rather compare to results published by Tanimoto
TE, et al. from Japan ( Table 7) [2-5,23-25].
Several studies have identified risk factors for GVHD
over the past 3 decades [21,26-33]. Gale et al. analyzed
data of 2036 recipients of HLA-identical sibling trans-
plants between 1978 and 1985 within the IBMTR. They
found donor/ recipient sex-match, patient age ≥40 years
and lack of GVHD prophylaxis to be associated with
moderate to severe GVHD [26]. Hahn et al. analyzed
IBMTR data of 1,960 adults after sibling HLA-identical
myeloablative transplant performed between 1995 and
2002. They reported risk factors for grade 2 to 4 acute
GVHD to be age 40 and older, use of total body irradi-
ation (TBI), grafting with mobilized blood cells , CML
versus AML/ALL, white/Black versus Asian/Hispanic race
(recipient), Karnofsky performance score less than 90





[5] n = 509
Couban et al.








CSA +MTX CSA +MTX CS
2-4 aGVHD(%) 23 32 ~ 37 44 52
3-4 aGVHD(%) 10 9 ~ 18 26 28
cGVHD(%) 67 42 ~ 62 85 67
extensive cGVHD
(%)
45 27 ~ 42 40 ns
OS(%) 71* 74* 68* 65
LFS(%) 70* 65 ~ 68* ns ns
NRM(%) 18 16 ~ 19 ns ns
*Standard risk patients.
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; H
NRM, non-relapse mortality; LFS, leukemia free survival; OS, overall survival; CsA, cycseronegative status [21]. Another study by Flowers et al.
analyzed 2941 adult and pediatric patients with both re-
lated and unrelated HLA –matched allo-HSCT performed
between 1992 and 2005 in Seattle [33]. Risk factors for de-
veloping grade 2 to 4 acute GVHD were unrelated donors,
use of TBI, lack of ATG utilization, female donor/male re-
cipient and the underlying diagnosis of CML. Concurring
with most other previous reports we determined in our
study the main risk factors for both aGVHD and cGVHD
to be age ≥ 40 years [21,26] . In contrast to most other re-
ports, we found that neither donor age, nor donor/recipi-
ent sex match, blood type match or CML enhanced the
likelihood for aGVHD, however, donor/recipient sex match
was associated with an increased risk of cGVHD. Whether
donor age impacts the risk of GVHD in our patient popu-
lation needs to be further studied. Kollman et al. reported
that donor age was associated with aGVHD and cGVHD
in unrelated donor HSCT [34]. Because all donors were
siblings, the age range for patients and donors in our study
remained in a relatively narrow range, and therefore our
sample size was insufficient for certain subset analysis.
However, we did not observe in recipients younger than
40 years of age any impact of the donor age on either
aGVHD or cGVHD. Our data suggest that the BuFlu con-
ditioning regimen significantly increases the incidence rates
for both aGVHD and cGVHD when compared with the
BuCy regimen. Such association has previously not been
reported in other studies and therefore these results need
to be interpreted with caution. In fact, Chae et al. reported
the opposite, that the BuFlu regimen decreased both inci-
dence rates of aGVHD as well as cGVHD when compared
with BuCy regimen [35]. On the other hand, Lee [36] and
Liu [37] found no significant differences for the incidence
rates of aGVHD and cGVHD between BuCy and BuFlu
conditioning regimens in two randomized trials.cal outcomes in selected studies for HLA-match sibling
hmitz et al.
] n = 163
Bensinger et al.
[2] n = 81
Yang et al.
[24] n = 68
Ringde′n et al.
[25] n = 1887
A +MTX CSA +MTX CSA +MTX CSA ±MTX
64 46 37 ~ 46
15 9 26 ~ 38
46 45 26 ~ 38
37 ns ns
* 66* 68 ns
65 62 33 ~ 49
21 ns 25 ~ 38
LA, human leukocyte antigen; HCST, hematopoietic stem cell transplantation;
losporine; MTX, methotrexate; MMF, mycophenolate mofetil.
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extensive cGVHD at 2 years at 67.4% and 45.1%, re-
spectively. Compared to some historic studies (Table 7),
at least this aspect of our study could be interpreted as
lack of improvement over current standards. The cumu-
lative incidences for cGVHD and extensive cGVHD
were slightly lower with 53.3% and 28.2% reported in
our prior study [14]. We explain this relatively high inci-
dence of cGVHD in our study with the fact that MMF
was only given for 30 days. However, this short course
was deliberately chosen to maintain some cGVHD in an
effort to maximize the GVL effect [38]. Another explan-
ation for this finding might be that all of our patients’
grafts were PBSCT based and consisted either of PBSCT
alone or PBCST + BM. Therefore higher rates of cGVHD
are expected compared to studies using pure BMT grafts
[15]. For instance, Wang Y et al. reported the incidence
for cGVHD at 50% for haploBMT [39]. There is no
study providing conclusive evidence regarding any dif-
ferences for the incidence of GVHD between Chinese
and Caucasian patients. However, a key factor deter-
mining development of cGVHD is the duration of im-
munosuppression. The design of our regimen prescribes
only a short course (30 days). Although the regimen is ef-
fective in preventing aGVHD, the remaining immunosup-
pression after MMF discontinuation may not have been
sufficient enough and thus resulted in the observed
cGVHD increase.
Although we found in our study grade 2–4 aGVHD to
be associated with lower rates of relapse mortality, this
also resulted in worse OS and LFS mainly due to in-
creased NRM. In contrast, we found that cGVHD was
associated with better OS and LFS outcomes which we
explain with concurrently decreased rates of relapse
mortality (Table 6). Nevertheless, these data have to be
interpreted with caution because 30.7% of our patients
had a diagnosis of CML, a disease known to be more
susceptible to GVL manipulations and the follow up has
been only 2 years. Moreover, other studies showed worse
survival for both cGVHD and aGVHD, despite a favor-
able association of cGVHD on disease relapse (AML and
MDS) [40]. Clearly, additional data need to be generated
to fine-tune GVHD regimens in order to maximize the
therapeutic benefit and find the optimal balance between
aGVHD, cGVHD and GVL.
Conclusion
In summary, although due to the study design a direct
comparison of the low dose short course MMF contain-
ing regimen to CsA/MTX alone for GVHD prophylaxis
could not be performed, we demonstrated a substantial
decrease for the risk of aGVHD development. In con-
trast, the incidence for cGVHD could not be improved
when compared to historical results in Chinese patients.Our results also suggest that Chinese patients may have
slight variations in risk factors for developing GVHD.
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